![Tatiana Zhuravskaya](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Tatiana Zhuravskaya
No más puestos en curso
Perfil
Tatiana Zhuravskaya is a Partner and Director of FDS Pharma.
She is Chief Executive Officer of ASGL-Research Laboratories.
Ms. Zhuravskaya is Chief Scientific Advisor of the Baltic Pharmaceutical Society.
She served as Non-Executive Director of Lipoxen Plc until October 6, 2008.
Prior to joining Lipoxen, Ms. Zhuravskaya worked as a Clinical Scientist at Public Health Laboratory Services (London).
From 1997 to 1998, she was a Clinical Researcher in the Neurology Department of the University of Pennsylvannia.
Ms. Zhuravskaya received a Medical Degree from the Medical School in St Petersburg and a PhD in Cell and Molecular Biology from the University of Nevada.
Antiguos cargos conocidos de Tatiana Zhuravskaya.
Empresas | Cargo | Fin |
---|---|---|
Xenetic Biosciences (UK) Ltd.
![]() Xenetic Biosciences (UK) Ltd. Pharmaceuticals: MajorHealth Technology Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom. | Director/Miembro de la Junta | 06/10/2008 |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Xenetic Biosciences (UK) Ltd.
![]() Xenetic Biosciences (UK) Ltd. Pharmaceuticals: MajorHealth Technology Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Tatiana Zhuravskaya